



A Leap from the Foundation to Fine Art
HBP SURGERY WEEK 2020

JULY 27-29, 2020 SEOUL DRAGON CITY, SEOUL, KOREA
www.khbps.org

& The 52nd Annual congress of the
Korean Association of HBP Surgery



Short Biosketch

Dr. Lijian Hui obtained his PhD degree from Shanghai Institute of Biochemistry and Cell Biology (SIBCB) and had Postdoc training at Institute of Molecular Pathology, Vienna. Dr. Hui was among the first to characterize the *in vivo* functions of p38 and JNK MAP kinases in liver tumorigenesis. After moving back to SIBCB at 2008, Dr. Hui focuses on understanding cell identity conversion in liver regeneration and tumorigenesis (Nature Cell Biology 2012; Hepatology 2013, 2016, Cell Stem Cell 2018, 2019;). His lab was the first to show the generation of functional hepatocytes (hiHeps) from cells of non-hepatic origin and the application of hiHeps in bio-artificial device for liver failure treatment (Nature 2011, Cell Stem Cell 2014, Cell Research 2016, 2017). Currently, his lab is working on new HCC cell line models (Cancer Cell 2019) and hiHep-based HCC/ICC organoid models (Nature Cell Biology 2019).